Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Y Zhou, L Tao, J Qiu, J Xu, X Yang, Y Zhang… - Signal transduction and …, 2024 - nature.com
Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …
tumors during tumorigenesis and progression, have been demonstrated to possess critical …
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Because genetic alterations including mutations, overexpression, translocations, and
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Background FGFR alterations are reported across various malignancies and might act as
oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine …
oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine …
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …
significant clinical attention in oncology due to their central role in cancer pathogenesis …
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Abstract Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …
Advances and challenges in targeting FGFR signalling in cancer
IS Babina, NC Turner - Nature Reviews Cancer, 2017 - nature.com
Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …
Personalized medicine: recent progress in cancer therapy
V Gambardella, N Tarazona, JM Cejalvo, P Lombardi… - Cancers, 2020 - mdpi.com
Translational research has revolutionized how we develop new treatments for cancer
patients. The change from an organ-centric concept guiding treatment choice towards deep …
patients. The change from an organ-centric concept guiding treatment choice towards deep …
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …
Signaling pathways and therapeutic approaches in glioblastoma multiforme
M Khabibov, A Garifullin… - International …, 2022 - spandidos-publications.com
Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is
associated with a poor clinical prognosis. Despite the progress in the understanding of the …
associated with a poor clinical prognosis. Despite the progress in the understanding of the …
The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing
T Helsten, S Elkin, E Arthur, BN Tomson… - Clinical cancer …, 2016 - aacrjournals.org
Purpose: Molecular profiling may have prognostic and predictive value, and is increasingly
used in the clinical setting. There are more than a dozen fibroblast growth factor receptor …
used in the clinical setting. There are more than a dozen fibroblast growth factor receptor …